Novavax (NVAX, $124.43) reports lower-than-expected Q2 revenue
Novavax reported revenue that increased substantially year-over-year, but was lower than analysts' expectations.
The vaccine development company’s revenue of $35.5 million in the latest quarter, compared to $3.4 million in the year-ago quarter. But the revenue was lower than Wall Street expectations.
During the quarter, the company experienced loss of -$17.5 million, or -30 cents a share share, compared to a net loss of -$39.6 million, or -$1.69 a share for the second quarter of 2019.
Research and development expenses climbed 15% to $34.8 million, primarily due to increased development activities relating to the coronavirus vaccine NVX-CoV2373, according to the company.
Last Friday, Novavax and Japanese drug company Takeda announced a partnership to develop, produce and commercialize Novavax's coronavirus-vaccine candidate in Japan.
According to Tickeron, NVAX's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram just turned negative
This is a Bearish indicator signaling NVAX's price could decline. Traders may explore shorting the ticker or looking at put options. In 38 of 39 cases where NVAX's MACD histogram became negative, the price fell further within the following month. The odds of a continued Downtrend are 90%.
Current price $124.43 is above $44.60 the highest support line found by A.I. Throughout the month of 07/10/20 - 08/11/20, the price experienced a +58% Uptrend, while the week of 08/04/20 - 08/11/20 shows a -5% Downtrend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator appears to be shifting from an Uptrend to a Downtrend. In 30 of 38 cases where NVAX's RSI indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 79%.
The Stochastic Indicator may be shifting from an Uptrend to a Downtrend. In 46 of 54 cases where NVAX's Stochastic indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 85%.
The higher Bollinger Band was broken -- a price fall is expected as the ticker heads toward the middle band, which invites the trader to consider selling or shorting the ticker, or exploring put options. In 35 of 41 cases where NVAX's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 85%.
Bullish Trend Analysis
The Aroon Indicator entered an Uptrend today. In 128 of 143 similar cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 71%. During the last month, the daily ratio of advancing to declining volumes was 1.85 to 1.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (49.59) is normal, around the industry mean (82.86). P/E Ratio (0.00) is within average values for comparable stocks, (78.26). Projected Growth (PEG Ratio) (0.00) is also within normal values, averaging (5.23). Dividend Yield (0.00) settles around the average of (0.08) among similar stocks. P/S Ratio (97.25) is also within normal values, averaging (1454.81).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
NVAX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for NVAX turned positive on July 03, 2025. Looking at past instances where NVAX's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on NVAX as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .
NVAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
NVAX moved below its 50-day moving average on July 07, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on June 25, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NVAX entered a downward trend on June 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.718). P/E Ratio (2.560) is within average values for comparable stocks, (58.312). NVAX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.371). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.937) is also within normal values, averaging (263.500).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of novel recombinant vaccines
Industry Biotechnology
Advertisement